Induction of oxidative stress by Taxol® vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 8, 2015, Pages 1925-1938

  Ilinskaya, Anna N ^a   Clogston, Jeffrey D ^a   McNeil, Scott E ^a   Dobrovolskaia, Marina A ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Abraxane ; Cremophor EL; Cytokines; Immunotoxicity; Interleukin 8; Oxidative stress; Paclitaxel; Taxol

Indexed keywords

NANOSTRUCTURED MATERIALS; NANOTECHNOLOGY; OXIDATIVE STRESS;

ABRAXANE; CREMOPHOR-EL; CYTOKINES; IMMUNOTOXICITY; INTERLEUKIN-8; PACLITAXEL;

MEDICAL NANOTECHNOLOGY;

CREMOPHOR; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG VEHICLE; GLYCEROL; IL8 PROTEIN, HUMAN; MACROGOL DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DRUG DOSAGE FORM COMPARISON; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; LYMPHOCYTE; MESSENGER RNA SYNTHESIS; MONOCYTE; MOUSE; NONHUMAN; NORMAL HUMAN; NORTHERN BLOTTING; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PEROXISOME; PHYSICAL CHEMISTRY; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CELL LINE; DRUG EFFECTS; METABOLISM; MONONUCLEAR CELL;

ALBUMIN-BOUND PACLITAXEL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; GLYCEROL; HUMANS; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MICE; OXIDATIVE STRESS; PACLITAXEL; PHARMACEUTICAL VEHICLES; POLYETHYLENE GLYCOLS;

EID: 84951077888     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.07.012     Document Type: Article

References (57)

1. Nehate C., Jain S., Saneja A., Khare V., Alam N., Dubey R., et al. Paclitaxel formulations: challenges and novel delivery options. Curr Drug Deliv 2014, 11:666-686.
2. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37:1590-1598.
3. Szebeni J., Muggia F.M., Alving C.R. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998, 90:300-306.
4. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
5. Dobrovolskaia M.A., McNeil S.E. In vitro assays for monitoring nanoparticle interaction with components of the immune system. Handbook of immunological properties of engineered nanomaterials 2013, 581-639. World Scientific Publishing, Singapore. M.L. Yarmush, D. Shi (Eds.).
6. Weiszhar Z., Czucz J., Revesz C., Rosivall L., Szebeni J., Rozsnyay Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci 2012, 45:492-498.
7. Szebeni J., Alving C.R., Savay S., Barenholz Y., Priev A., Danino D., et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001, 1:721-735.
8. Manthey C.L., Qureshi N., Stutz P.L., Vogel S.N. Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophages. J Exp Med 1993, 178:695-702.
9. Perera P.Y., Mayadas T.N., Takeuchi O., Akira S., Zaks-Zilberman M., Goyert S.M., et al. CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol 2001, 166:574-581.
10. Manthey C.L., Brandes M.E., Perera P.Y., Vogel S.N. Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J Immunol 1992, 149:2459-2465.
11. Ding A.H., Porteu F., Sanchez E., Nathan C.F. Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 1990, 248:370-372.
12. Perera P.Y., Vogel S.N., Detore G.R., Haziot A., Goyert S.M. CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol. J Immunol 1997, 158:4422-4429.
13. Kawasaki K., Akashi S., Shimazu R., Yoshida T., Miyake K., Nishijima M. Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol. J Endotoxin Res 2001, 7:232-236.
14. O'Brien J.M., Wewers M.D., Moore S.A., Allen J.N. Taxol and colchicine increase LPS-induced pro-IL-1 beta production, but do not increase IL-1 beta secretion. A role for microtubules in the regulation of IL-1 beta production. J Immunol 1995, 154:4113-4122.
15. Bhat N., Perera P.Y., Carboni J.M., Blanco J., Golenbock D.T., Mayadas T.N., et al. Use of a photoactivatable taxol analogue to identify unique cellular targets in murine macrophages: identification of murine CD18 as a major taxol-binding protein and a role for Mac-1 in taxol-induced gene expression. J Immunol 1999, 162:7335-7342.
16. Byrd-Leifer C.A., Block E.F., Takeda K., Akira S., Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001, 31:2448-2457.
17. Zaks-Zilberman M., Zaks T.Z., Vogel S.N. Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine 2001, 15:156-165.
18. Dinarello C.A. Proinflammatory cytokines. Chest 2000, 118:503-508.
19. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
20. Aggarwal B.B., Gupta S.C., Kim J.H. Historical perspectives on tumor necrosis factor and its superfamily: 25years later, a golden journey. Blood 2012, 119:651-665.
21. Gales D., Clark C., Manne U., Samuel T. The chemokine CXCL8 in carcinogenesis and drug response. ISRN Oncol 2013, 2013:1-8.
22. Henricson B.E., Carboni J.M., Burkhardt A.L., Vogel S.N. LPS and Taxol activate Lyn kinase autophosphorylation in Lps(n), but not in Lpsd), macrophages. Mol Med 1995, 1:428-435.
23. Allen J.N., Moore S.A., Wewers M.D. Taxol enhances but does not induce interleukin-1 beta and tumor necrosis factor-alpha production. J Lab Clin Med 1993, 122:374-381.
24. Zimmer S.M., Liu J., Clayton J.L., Stephens D.S., Snyder J.P. Paclitaxel binding to human and murine MD-2. J Biol Chem 2008, 283:27916-27926.
25. Piro S., Anello M., Di Pietro C., Lizzio M.N., Patane G., Rabuazzo A.M., et al. Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism 2002, 51:1340-1347.
26. Schrader M., Fahimi H.D. Peroxisomes and oxidative stress. Biochim Biophys Acta 1763, 2006:1755-1766.
27. Said T., Dutot M., Christon R., Beaudeux J.L., Martin C., Warnet J.M., et al. Benefits and side effects of different vegetable oil vectors on apoptosis, oxidative stress, and P2X7 cell death receptor activation. Invest Ophthalmol Vis Sci 2007, 48:5000-5006.
28. Allen R.G., Tresini M. Oxidative stress and gene regulation. Free Radic Biol Med 2000, 28:463-499.
29. Dean J.L., Sully G., Clark A.R., Saklatvala J. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 2004, 16:1113-1121.
30. Hitti E., Iakovleva T., Brook M., Deppenmeier S., Gruber A.D., Radzioch D., et al. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol 2006, 26:2399-2407.
31. Hoffmann E., Dittrich-Breiholz O., Holtmann H., Kracht M. Multiple control of interleukin-8 gene expression. J Leukoc Biol 2002, 72:847-855.
32. Albanyan E.A., Vallejo J.G., Smith C.W., Edwards M.S. Nonopsonic binding of type III Group B Streptococci to human neutrophils induces interleukin-8 release mediated by the p38 mitogen-activated protein kinase pathway. Infect Immun 2000, 68:2053-2060.
33. Muselet-Charlier C., Roque T., Boncoeur E., Chadelat K., Clement A., Jacquot J., et al. Enhanced IL-1beta-induced IL-8 production in cystic fibrosis lung epithelial cells is dependent of both mitogen-activated protein kinases and NF-kappaB signaling. Biochem Biophys Res Commun 2007, 357:402-407.
34. Bhattacharyya S., Gutti U., Mercado J., Moore C., Pollard H.B., Biswas R. MAPK signaling pathways regulate IL-8 mRNA stability and IL-8 protein expression in cystic fibrosis lung epithelial cell lines. Am J Physiol Lung Cell Mol Physiol 2011, 300:L81-L87.
35. Katome T., Namekata K., Guo X., Semba K., Kittaka D., Kawamura K., et al. Inhibition of ASK1-p38 pathway prevents neural cell death following optic nerve injury. Cell Death Differ 2013, 20:270-280.
36. Chow S., Patel H., Hedley D.W. Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry 2001, 46:72-78.
37. Tan Z., Qian X., Jiang R., Liu Q., Wang Y., Chen C., et al. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol 2013, 191:1835-1844.
38. Freund A., Chauveau C., Brouillet J.P., Lucas A., Lacroix M., Licznar A., et al. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 2003, 22:256-265.
39. Sethi G., Shanmugam M.K., Ramachandran L., Kumar A.P., Tergaonkar V. Multifaceted link between cancer and inflammation. Biosci Rep 2012, 32:1-15.
40. Cheng X.S., Li Y.F., Tan J., Sun B., Xiao Y.C., Fang X.B., et al. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial-mesenchymal transition. Cancer Lett 2014, 348:77-87.
41. Veltri R.W., Miller M.C., Zhao G., Ng A., Marley G.M., Wright G.L., et al. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 1999, 53:139-147.
42. Ferrajoli A., Keating M.J., Manshouri T., Giles F.J., Dey A., Estrov Z., et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002, 100:1215-1219.
43. Wang Y., Qu Y., Niu X.L., Sun W.J., Zhang X.L., Li L.Z. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 2011, 56:365-375.
44. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
45. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
46. Jung Y.J., Isaacs J.S., Lee S., Trepel J., Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003, 17:2115-2117.
47. Angst E., Reber H.A., Hines O.J., Eibl G. Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery 2008, 144:57-65.
48. Bigatto V., De Bacco F., Casanova E., Reato G., Lanzetti L., Isella C., et al. TNF-alpha promotes invasive growth through the MET signaling pathway. Mol Oncol 2015, 9:377-388.
49. Kawasaki K., Akashi S., Shimazu R., Yoshida T., Miyake K., Nishijima M. Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem 2000, 275:2251-2254.
50. Rajput S., Volk-Draper L.D., Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther 2013, 12:1676-1687.
51. Wang A.C., Ma Y.B., Wu F.X., Ma Z.F., Liu N.F., Gao R., et al. TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma. Oncol Lett 2014, 7:871-877.
52. Kelly M.G., Alvero A.B., Chen R., Silasi D.A., Abrahams V.M., Chan S., et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006, 66:3859-3868.
53. Aggarwal B.B., Shishodia S., Takada Y., Banerjee S., Newman R.A., Bueso-Ramos C.E., et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005, 11:7490-7498.
54. Wang A.C., Su Q.B., Wu F.X., Zhang X.L., Liu P.S. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells. Eur J Clin Invest 2009, 39:157-164.
55. Miskolci V., Hodgson L., Cox D., Vancurova I. Western analysis of intracellular interleukin-8 in human mononuclear leukocytes. Methods Mol Biol 2014, 1172:285-293.
56. Siddiqui R.A., Akard L.P., Garcia J.G., Cui Y., English D. Chemotactic migration triggers IL-8 generation in neutrophilic leukocytes. J Immunol 1999, 162:1077-1083.
57. DeForge L.E., Fantone J.C., Kenney J.S., Remick D.G. Oxygen radical scavengers selectively inhibit interleukin 8 production in human whole blood. J Clin Invest 1992, 90:2123-2129.